Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOLDEN-AGE: SGLT-2 Inhibitors in Elderly T2DM
NCT04796428Phase 4Unknown
- Sponsor
- Center for Outcomes Research and Clinical Epidemiology
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of canagliflozin, dapagliflozin and empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Center for Outcomes Research and Clinical Epidemiology. Status: unknown.
02
Drugs
canagliflozindapagliflozinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04796428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796428.